DOI:
10.1055/s-00000002
Aktuelle Dermatologie
LinksClose Window
References
Verstovsek S, Passamonti F, Rambaldi A. et al.
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Cancer 2014;
120: 513-520
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.